Abstract In this study, we investigated the anti-atopic dermatitis (AD) activity of b-glucans derived from Aureobasidium pullulans SM-2001 (bGdAP). bGdAP was orally administered to AD animal models such as vasodilation, allergic pruritus and contact dermatitis. Administration of bGdAP attenuated the amount of Evans blue solution on vasodilation rat. Scratching behaviors, secretion of histamine and ear thickness were significantly (p \ 0.05) attenuated in the bGdAP-treated mouse groups. Interestingly, transcriptional expression of T-bet, a transcription factor for Th1 reactions, was increased, but that of GATA-3, a transcription factor for Th2 reactions, was attenuated in the bGdAP-treated groups (p \ 0.05). In addition, we found that reduced transcriptional expression of forkhead box P3 and galectin-9, regulators of regulatory T cells, was recovered in the bGdAP-treated groups (p \ 0.05). Taken together, these data indicate that administration of bGdAP could effectively attenuate ADlike phenotypes via regulation of Th1/Th2 transcriptional activity and Treg activation.
Introduction
Atopic dermatitis (AD) is a chronic relapsing disease that is characterized by xeroderma, pruritus, and inflammation [1] . Although the detailed mechanisms of AD disease are still not clear, various factors such as air pollution, allergens in housing environment, and stress have been suggested as critical factors that exacerbating AD symptoms [2] . From the immunological perspective, AD is induced by an imbalance of Th1/Th2 cells that is caused by inhibition of the proliferation and differentiation of Th1 cells along with the release of diverse Th2 cytokines such as interleukin-4 (IL-4), IL-5, and IL-13 [3, 4] . In addition, regulatory T cells (Tregs) that are positive for foxhead box P3 (FOXP3) have been reported to play critical roles in immunosuppressive function [5] . FOXP3 is a well-known transcription factor that is associated with the activation of Tregs [6] . Moreover, expression of galectin-9 in intestinal epithelial cells has been reported to play an immunomodulatory role in Treg polarization [7] . Therefore, agents that activate FOXP3 and galectin-9 expression may be useful for alleviating the symptoms of AD.
AD is primarily treated with local steroids including calcineurin inhibitors, antihistamines, c-linolenic acid, cyclosporine, and interferon gamma (IFN-c). However, these therapies often result in relapse when discontinued, or cause side effects when used for a long time [8] . Therefore, there is growing interest in natural remedies for AD that can regulate inflammation-related cytokine expression and have minimal side effects. One such compound that has attracted attention is b-glucan, which is a biologically active polysaccharide present in the cell wall of yeasts, mushrooms, cereals, algae, and a few bacteria [9] [10] [11] . bGlucan can activate the immune functions of normal human cellular tissues to inhibit the proliferation of cancer cells, prevent relapse of cancer, and promote the production of IFN-c and IL, which are known to indirectly inhibit the proliferation of cancer cells [12, 13] . b-Glucan has been reported to have role in innate immune responses through activating B-lymphocytes [14] . b-Glucan has also been found to have anti-hyperlipidemic effects [15] , anti-obesity effects via inhibition of the formation and accumulation of body fat [16] , anti-oxidative activity [17] , and arthritisalleviating effects [18] ; thus, it can be used as a health food ingredient and a food additive.
The exopolymer of Aureobasidium pullulans SM-2001 is mainly composed of b-1,3-and b-1,6-glucans and has been reported to have anti-osteoporotic effects [19] and inhibitory effects against UVB-induced skin damage [20] . However, despite there being evidence for the diverse effects of b-glucans derived from A. pullulans SM-2001 (bGdAP), there is not enough information about its immunomodulatory effects in atopic dermatitis disease models. Therefore, in the present study, several AD-like phenotypes were induced in rats and mice, and bGdAP was orally administered in order to investigate its immunomodulatory effects.
Materials and methods

Reagents
The compound 48/80 (COM), Evans blue solution, dinitrofluorobenzene (DNFB), and aluminum hydroxide gel were obtained from Sigma-Aldrich (CA, USA), and dinitrophenyl-derivatized ovalbumin (DNP-OVA) were purchased from Alpha diagnostic Intl. Inc., USA.
Animals and treatment
Six-week-old Sprague-Dawley (SD) male rats from Samtako (Osan, Korea) and six-week-old male ddY mice from Central Lab. Animal Inc. (Seoul, Korea) were purchased for the experiment. During the acclimation and experimental periods, a room temperature of 22 ± 1°C, humidity of 60 ± 10%, and a 12-h light/12-h dark cycle were maintained. The animals were given free access to pellettype solid feed AIN-76A (Choongang Co., Seoul, Korea) and water. After an acclimation period of 1 week, the experimental animals were divided into six groups of ten animals each: (1) Control group (C: normal diet), (2) Negative control group (N: normal diet ? AD induction), (3) Positive control group (P: normal diet ? 0.2 mg/kg body weight of Zyrtec ? AD induction), (iv) bGdAP treatment group 1 (T1: normal diet ? 1 mg/kg body weight of bGdAP ? AD induction), (v) bGdAP treatment group 2 (T2: normal diet ? 10 mg/kg body weight of bGdAP ? AD induction), and (vi) bGdAP treatment group 3 (T3: normal diet ? 20 mg/kg body weight of bGdA-P ? AD induction). Zyrtec (cetirizine) (UCB FARCHIM S.A., Switzerland) was used to attenuate the AD-like symptoms. Macromolecular bGdAP polymers externally secreted from the black yeast strain A. pullulans SM-2001 with an average molecular weight of 2.6 9 10 5 Da were obtained from Glucan Co. (Seoul, Korea) [21] . The doses of bGdAP, which used in this study, were determined by considering the guideline for adults from Glucan Co. 
Histamine-induced vasodilation
The compound 48/80 (COM), which promotes histamine secretion, was used to induce the AD-like phenotype in the SD rats according to the method of Ishiguro et al. [22] . Briefly, Zyrtec and bGdAP were orally administered to the positive control (P) and bGdAP groups (T1, T2, and T3) respectively. At 1 h after Zyrtec and bGdAP administration, COM (10 lg/mL) at a dose of 50 ll was intra-dermally injected into the shaved dorsal dermis of rats once every 7 days. At 30 min after the COM injection, 200 ll of Evans blue solution was injected into the tail vein, and all the animals were sacrificed 30 min later. The dorsal dermis was cut out 30 min later to measure the diameters of the spots (in millimeters) representing extravasation of the blue dye due to vasodilation, using a digital caliper (Bluebird, NA500-150S). To measure the amount of leaked dye, the dorsal dermis of each animal was cut in a 10-mm diameter circle, and the cut pieces were kept in a 1.0 N KOH (1.0 mL) solution at 37°C for 48 h to initiate the reaction. Then, 0.6 N H 3 PO 4 (2.5 mL) and acetone (6.5 mL) were added to the reaction mixture, which was shaken and centrifuged at 9009g for 10 min. The absorbance of the supernatant was determined at 620 nm by spectrophotometric analysis (iMAX microplate reader, Biorad co., Korea) to measure the amount of blue dye that had leaked in milligrams per site. To measure the level of serum histamine, the animals were sacrificed at 30 min after the administration of Evans blue, and blood samples taken from the vena cava were centrifuged for 15 min at 13009g to separate the serum. The level of histamine in the separated serum was measured using Histamine EIA Kits (LDN, Germany).
Mouse model of allergic pruritus
The histamine secretion promoter COM (3 mg/kg body weight) was subcutaneously injected into the shaved dorsal dermis of ddY mice to induce the AD-like phenotype. Zyrtec and bGdAP were orally administered once a day for 7 days. At 30 min after COM administration, the number of reactions (expressed in the form of pruritus) in the entire body was counted for 20 min. When the animals were sacrificed 30 min after Evans blue administration, blood samples taken from the vena cava were centrifuged for 15 min at 13009g to separate the serum. The level of histamine in the separated serum was measured using Histamine EIA Kits (LDN, Germany).
Mouse model of contact dermatitis
To induce contact dermatitis, which is an AD-like phenotype, the ddY mice were sensitized by intraperitoneal injection of 0.2 mL of saline solution containing 10 lg DNP-OVA and 1 mg of aluminum hydroxide gel. Seven days after sensitization, 10 ll of 0.1% 2,4-DNFB dissolved in ethanol was applied to the ear and paw regions. Ear thickness was measured before DNFB application and 1 h and 24 h after DNFB application using a digital caliper (Bluebird, NA500-150S). Immediately after the DNFB application, the number of reactions (in the form of pruritus) on the entire body within a span of 1 h was counted according to a previously reported method [23] .
RNA isolation and analysis
To analyze the immunomodulatory effects of bGdAP, rats with vasodilation were sacrificed, and their mesenteric lymph nodes were resected. The separated mesenteric lymph nodes were placed in Trizol Ò Reagent (Ambion, CA, USA) and homogenized using SilentCrusher M (Heiodlph, Schwabach, Germany). RNA was isolated using the total RNA isolation kit (Intronbio Co., Sungnam, Korea) and stored at -20°C until use for cDNA synthesis (TaKaRa Co., Tokyo, Japan). Quantitation was performed using a CFX connect real-time system (Bio-Rad Co., CA, USA) with the SYBR Green real-time master mix (Toyobo Co., Tokyo, Japan). Relative expression of each gene was determined by using the comparative Ct method and normalized to the expression of GAPDH. The sequences of the T-bet primers are 5 0 -CCACCCAGAAGACTGTGGAT-3 0 (forward) and 5 0 -CACATTGGGGGTAGGAACAC-3 0 (reverse); GATA-3 primers, 5
0 -CATTACCACCTATCCGCC CTATG-3 0 (forward) and 5 0 -CACACACTCCCTGCCTTC TGT-3 0 (reverse); FOXP3 primers, 5 0 -CCCATCCCCAG GAGTCTTG-3 0 (forward) and 5 0 -CCATGACTAGGGGC ACTGTA-3 0 (reverse); galectin-9 primers, 5 0 -GAGAGGA AGACACACATGCCTTTC-3 0 (forward) and 5 0 -GACCA CAGCATTCTCATCAAAACG-3 0 (reverse); GAPDH primers, 5
0 -CCACCCAGAAGACTGTGGAT-3 0 (forward) and 5 0 -CACATTGGGGGTAGGAACAC-3 0 (reverse).
Statistical analysis
The variance of the data obtained through repeated experiments was analyzed using SPSS 12.0 (SPSS Inc., IL, USA), and the results are represented as the mean ± standard deviation values. The significance was determined by analysis of variance followed by Duncan's multiple range test at the level of p \ 0.05.
Results and discussion
Effects of bGdAP on COM-induced vasodilation
To analyze the effects of bGdAP on vasodilation, an ADlike phenotype, rats in which vasodilation was induced were orally administered bGdAP (one group of control rats was not administered bGdAP). The degree of vasodilation was determined by measuring the size of the spots containing leaked Evans blue. As shown in Fig. 1(A) , there was no dye leakage in the control group (C), and the largest blue-dye spots (largest diameter, 5.31 mm) were observed in the COM-treated groups (N). The diameter of the spots significantly (p \ 0.05) decreased on Zyrtec administration in the positive control groups. Among the bGdAP groups, T1 had the smallest blue-dye spot diameter of 3.81 mm, which indicates the lowest degree of vasodilation and therefore the greatest degree of inhibition against vasodilation. To determine the amount of Evans blue dye that had leaked, the dorsal dermis of the rats was resected and dissolved in an alkaline solution, and the absorbance of the supernatant was determined through spectrophotometric analysis. The positive control group (P) had the lowest amount of dye (0.024 mg/site), while the negative control groups (N) had the highest amount of dye (0.248 mg/site) and exhibited remarkable AD-like symptoms [ Fig. 1(B) ]. Histamine, which is mainly secreted by mast cells and basophilic cells, is the main factor that causes vasodilation in AD. To further investigate the effects of bGdAP on vasodilation, the concentration of serum histamine was measured in each group. As shown in Fig. 1(C) , the COMtreated negative control group (N) showed the highest level Effect of oral administration of b-glucans 1187 of serum histamine (28.09 ng/mL), and the positive control (P) and bGdAP groups (T1, T2, and T3) showed lower levels of serum histamine than the N group (p \ 0.05). In an experiment conducted using type I dermatitis models with passive cutaneous anaphylaxis, it was reported that remarkable extravasation of the blue dye due to vasodilation occurred 30 min after exposure to the antigen [24] . The significant decreases in the diameter of the leaked dye spots and the amount of leaked blue dye shown in the present experiment can be considered as direct evidence of the effects of bGdAP on the inhibition of vasodilation, which represents the acute inflammatory changes caused by AD. Taken together, these data indicate that administration of bGdAP was effective for attenuating vasodilation, an AD-like phenotype.
Effects of bGdAP on allergic pruritus
To further confirm the effects of bGdAP on AD-like phenotypes, scratching behaviors were examined using a mouse model of allergic pruritus. As shown in Fig. 2(A) , the COM-treated mouse group (N) showed the most frequent scratching behaviors, while the other mouse groups (P, T1, T2, and T3) showed significantly (p \ 0.05) less frequent scratching behaviors than the COM-treated mouse group (N). Figure 2 (B) shows the levels of serum histamine, which is a factor that causes allergic pruritus, in the different groups. The N group showed significantly higher levels of histamine than the other groups (p \ 0.05). In the case of AD, mast cells sensitized by IgE secrete histamine, and this leads to the development of symptoms such as edema, erythema, and pruritus [25] . In particular, histamine secretion induced by COM leads to edematous changes [26] . In the present experiment, the significant decrease observed in the serum histamine levels in the treatment and P groups compared to the N group was direct evidence of the effects of bGdAP on the inhibition of the series of reactions caused by AD. These findings indicate that bGdAP alleviates inflammation. COM is known to promote histamine secretion from mast cells. In addition, COM promotes histamine secretion to induce scratching behaviors in mice [27] . The decrease in scratching behaviors in AD mice treated with bGdAP indicates that bGdAP has a positive effect on allergic pruritus [28] . In the present experiment, scratching behaviors significantly decreased in the AD group in which bGdAP was orally administered compared to the AD group that was not treated with bGdAP. Therefore, bGdAP appears to have inhibitory effects on COM-induced pruritus. These results indicate that administration of bGdAP can attenuate allergic pruritus, which is an AD-like phenotype.
Effects of bGdAP on contact dermatitis
Finally, we tested the effects of bGdAP on AD-like phenotypes, using the DNP-OVA-and DNFB-induced mouse model of contact dermatitis. Ear thicknesses was measured twice, at 1 h and 24 h after DNFB treatment. The ear thicknesses of the DNP-OVA-and DNFB-treated mouse group (N) dramatically increased compared to the control mouse group (C) (p \ 0.05). However, it was significantly decreased in the P and bGdAP-treated mouse groups (T1, T2, and T3) (p \ 0.05) [ Fig. 3(A) ]. To investigate pruritus associated with contact dermatitis induced by DNP-OVA and DNFB, signs of pruritus were observed for 1 h after DNFB treatment. In the P and bGdAP-treated groups (T1, T2, and T3), pruritus was significantly (p \ 0.05) alleviated compared to the DNFB-treated mouse group (A) (B) (C) Fig. 3(B) ]. When DNFB was repeatedly applied to the ears of the mice, the increase in the level of serum IgE induced an increase in the thickness of the ears. Similarly, it has been reported that repeated DNFB application induces epidermal thickening, scab formation, and inflammatory cell infiltration [29] . DNFB-induced contact dermatitis models are useful for the evaluation of type I allergic dermatitis. When DNFB is applied to the ears of mice sensitized with DNP-OVA, two types of edema are induced: the edema that occurs 1 h after DNFB application is called the immediate-phase response (IPR), and the edema that occurs 24 h after DNFB application is called the late-phase response (LPR) [30] . After DNFB application, scratching behaviors are observed during IPR, which is an inflammatory reaction caused by the chemical mediators released from mast cells. In the present experiment, bGdAP inhibited edema in both IPR and LPR and significantly inhibited scratching behaviors in IPR. Therefore, the present data indicate that administration of bGdAP can alleviate the DNFB-induced contact dermatitis phenotype.
Changes in transcriptional activity in bGdAPadministered rat groups
To investigate the mechanisms through which bGdAP alleviates AD-like phenotypes, the expression of T-bet and GATA-3, as transcription factors of Th1 and Th2 cells, respectively, was examined in the mesenteric lymph node tissues of rats with vasodilation. As shown in Fig. 4 , T-bet, a transcription factor associated with Th1 reactions, showed significantly (p \ 0.05) higher expression in the bGdAP groups (T1, T2 and T3) than in the negative control group (N). However, GATA-3, a transcription factor associated with Th2 reactions, showed significantly (p \ 0.05) lower expression in the bGdAP groups (T1, T2 and T3) than in the negative control group (N). Based on the T-bet/GATA-3 expression ratio, the Th1/Th2 transcriptional ratio was found to be significantly (p \ 0.05) decreased in the AD-induced negative control group (N), but it dramatically recovered in the bGdAP-treated groups (T1, T2 and T3) [ Fig. 4(C) ]. Cytokines are substances produced mostly by immune cells that are closely related to immune regulation. Th1 cell cytokines are known to enhance cellular immune responses and inhibit allergy-related cellular immune responses [31] . Further, Th2 cells secrete cytokines to promote the inflow and activation of allergy-related cells, such as B cells, mast cells, and eosinophils, and cause damage to tissues through fibrosis [32] . Activated immune cells release IgE, histamine, and cytotoxic substances to (A) (B) (C) Significant differences between means at p \ 0.05. Data represent the mean ± SD values from four replicates intensify the inflammatory responses and induce clinical signs [33] . Therefore, inhibiting Th2 cell action that is central to allergic reactions is essential for the treatment of allergic diseases. In the present study, bGdAP inhibited Th2 cell reactions that are central to allergic reactions that have immunomodulatory effects.
Stimulation of FOXP3 and galectin-9 expression by administration of bGdAP To determine the effects of bGdAP on the activation of Tregs, transcriptional changes in FOXP3, a transcription factor of Tregs, and galectin-9, which is known as a stimulator of Treg activation, were investigated in the mesenteric lymph nodes of rats with vasodilation. As shown in Fig. 5 , the expression levels of FOXP3 and galectin-9 were significantly (p \ 0.05) attenuated in the AD-induced group (N) compared with the control group (C). However, FOXP3 and galectin-9 expression was dramatically recovered in the bGdAP groups (T1, T2 and T3) (p \ 0.05). FOXP3 is a well-known specific marker of Tregs, and FOXP3-positive Tregs have been reported to play an important role in immune tolerance [34] . Further, activation of FOXP3-positive Tregs was effective in reducing disease severity in inflammatory bowel disease and animal models of asthma [35] . Dietary synbiotics such as galacto-and fructo-oligosaccharides have been reported to have suppressive effects on allergic symptoms in mice and humans via upregulation of the expression of galectin-9 [36] . Since activation of Treg and galectin-9 expression may be useful for suppressing the immune responses in AD, our data indicate that administration of bGdAP may activate Tregs via stimulation of the transcriptional expression of FOXP3 and galectin-9, which may result in the attenuation of AD-like phenotypes.
Overall, in the present study, we investigated the effects of bGdAP against AD-like phenotypes by using three AD animal models. Oral administration of bGdAP in a COM-induced AD rat model significantly reduced vasodilation, which is an acute inflammatory change caused by AD, and allergic pruritus. We found that contact dermatitis was also significantly attenuated with bGdAP treatment. Taken together, we believe that these results, to the best of our knowledge, are the first to demonstrate the anti-AD effects of bGdAP via regulation of the expression of Th1/Th2 and activators of Tregs.
